(Q33361449)

26 July 2017

title

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas (English)

1 reference

26 July 2017

0 references

1 reference

Eric T Wong

1

1 reference

26 July 2017

Roy Tishler

series ordinal

2

1 reference

26 July 2017

Loretta Barron

series ordinal

3

1 reference

26 July 2017

Julian K Wu

series ordinal

4

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

101

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

139-145

1 reference

Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

First-line therapy with temozolomide induces regression of primary CNS lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

Combined modality therapy for primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

PCV salvage chemotherapy for recurrent primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Endothelial vesicles in the blood-brain barrier: are they related to permeability?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20339

7 January 2021

Identifiers

DOI

10.1002/CNCR.20339

1 reference

26 July 2017

1 reference